Literature DB >> 2035723

Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.

D C Goff1, K K Midha, A W Brotman, M Waites, R J Baldessarini.   

Abstract

Fluoxetine (20 mg/day) was added for 7-10 days to stable doses of haloperidol given to eight psychotic patients. Mean plasma concentrations of haloperidol were elevated by 20% (p less than 0.05), but extrapyramidal side effects did not increase appreciably, indicating a relatively minor interaction between these agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2035723     DOI: 10.1176/ajp.148.6.790

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  22 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.

Authors:  Abdo Haddad; Mellar Davis; Ruth Lagman
Journal:  Support Care Cancer       Date:  2006-12-01       Impact factor: 3.603

3.  Schizophrenia with obsessive compulsive features.

Authors:  Michael Y Hwang; Sun Young Yum; Miklos F Losonczy; Grant Mitchell; Jun Soo Kwon
Journal:  Psychiatry (Edgmont)       Date:  2006-09

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 5.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.

Authors:  J Fang; G B Baker; P H Silverstone; R T Coutts
Journal:  Cell Mol Neurobiol       Date:  1997-04       Impact factor: 5.046

7.  Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients.

Authors:  S Härtter; H Wetzel; E Hammes; C Hiemke
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 8.  Clinical pharmacokinetics of fluoxetine.

Authors:  A C Altamura; A R Moro; M Percudani
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

Review 9.  Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

Authors:  L Ereshefsky; C Riesenman; Y W Lam
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 10.  Management of the negative symptoms of schizophrenia: new treatment options.

Authors:  Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.